StarClose SE Vascular Closure System
Abbott Vascular Devices · Decision date Mar 2, 2026
What did the FDA decide?
FDA records P050007/S048 as a supplement to PMA P050007, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Mar 2, 2026.
FDA approval order statement
a modification to the sustainable ethylene oxide (SEO) cycle previously approved for Line 1, Line 2, Line 14 and Line 15 at Synergy Health Ireland and implementation of the SEO cycle at Sterigenics Los Angeles
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Mar 2, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P050007/S048
- Regulatory pathway
- PMA supplement
- Applicant
- Abbott Vascular Devices
- Product code
- MGB
- Decision code
- OK30
- Decision date
- Mar 2, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Device, hemostasis, vascular.
- Applicant
- Abbott Vascular Devices
- Product code
- MGB
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P050007/S047 · Related supplement
StarClose SE Vascular Surgical System
P050007/S048 received
Application receipt date recorded by FDA.
P050007/S048 · FDA decision
30-Day Notice
P050007/S049 · Related supplement
StarClose SE Vascular Closure System
Timeline entries are records held by MedtechLedger for P050007. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P050007
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
StarClose SE Vascular Surgical SystemP050007/S047 | Abbott Vascular Devices | PMA supplement | Dec 9, 2025 | FDA |
StarClose SE Vascular Closure SystemP050007/S049 | Abbott Vascular Devices | PMA supplement | Apr 17, 2026 | FDA |
Explore the linked device profile
Other records with product code MGB
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Abbott Vascular, Inc. | PMA supplement | Nov 4, 2026 | FDA | |
CELT ACD VASCULAR CLOSURE DEVICEP150006/S009 | Vasorum, Ltd. | PMA supplement | Oct 30, 2026 | FDA |
| Abbott Vascular, Inc. | PMA supplement | Oct 26, 2026 | FDA | |
| Vivasure Medical , Ltd. | PMA approval | Oct 16, 2026 | FDA | |
| Abbott Vascular, Inc. | PMA supplement | Sep 24, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Vascular Devices
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 3200 Lakeside Dr., Santa Clara, CA, 95054
Sources and methodology
- Original FDA record: P050007/S048
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


